The Complete GLP-1 Supplement Guide

GLP-1 medications are transforming metabolic health in South Africa — but they create nutritional gaps that most users don't know about. This guide explains what's happening in your body, which nutrients are at risk, and exactly what to take to protect your results.

1. What GLP-1 Medications Do to Your Body

GLP-1 (glucagon-like peptide-1) receptor agonists work by mimicking a natural gut hormone released after eating. When you inject semaglutide, tirzepatide, or newer agents like retatrutide, here's what happens at a physiological level:

• Gastric emptying slows dramatically — food stays in your stomach longer, reducing appetite signals and post-meal glucose spikes.
• Insulin secretion becomes glucose-dependent — the pancreas releases insulin only when blood sugar rises, reducing hypoglycaemia risk.
• Glucagon is suppressed — the liver produces less glucose between meals.
• Appetite centres in the brain are directly affected — semaglutide and tirzepatide act on hypothalamic receptors, reducing hunger independently of gastric effects.
• Tirzepatide adds GIP receptor agonism — a dual mechanism that drives more aggressive fat loss and metabolic remodelling compared to GLP-1 alone.
• Retatrutide adds glucagon receptor activation — a triple mechanism currently in Phase 3 trials, showing unprecedented weight loss outcomes.

The result is powerful. Clinical trials show 15–22% body weight reductions over 68 weeks with semaglutide, and up to 22.5% with tirzepatide. But the same mechanisms — reduced food intake, slower digestion, altered gut environment — create real nutritional vulnerabilities that require active management.

2. The 6 Key Nutrient Depletions

Vitamin B12, B6 & Folate

GLP-1 medications reduce gastric acid secretion and slow gut motility. Both are essential for B12 absorption: stomach acid releases B12 from food proteins, and intrinsic factor (produced in the stomach lining) must bind B12 for absorption in the small intestine. When intake drops and absorption efficiency falls simultaneously, deficiency develops faster than expected. B6 and folate are critical co-factors in homocysteine metabolism — elevated homocysteine is an independent cardiovascular risk factor. Together, these three B vitamins support neurological function, red blood cell production, and cellular energy.

Deficiency symptoms: Fatigue, brain fog, tingling in hands/feet, mood changes, anaemia.

Magnesium

Magnesium participates in over 300 enzymatic reactions — including ATP production, glucose metabolism, muscle contraction, and DNA synthesis. GLP-1 users face a double burden: reduced dietary magnesium from decreased food intake, and increased magnesium demand from accelerated metabolic activity during weight loss. Liposomal delivery forms significantly improve absorption versus standard magnesium oxide. For GLP-1 users, a combination formula addressing both daily requirements and cellular uptake is ideal.

Deficiency symptoms: Muscle cramps and twitching, poor sleep, anxiety, constipation (already common on GLP-1s), fatigue.

Vitamin D3 & K2

Both vitamins are fat-soluble — they're stored in adipose tissue and released as fat is mobilised during weight loss. This provides a temporary supply, but as fat mass decreases rapidly on GLP-1 medications, these stores deplete. Vitamin D3 is critical for muscle fibre function (particularly fast-twitch fibres), calcium absorption, immune regulation, and mood. K2 (as MK-7) activates osteocalcin and matrix GLA protein — ensuring calcium is deposited into bones rather than arterial walls. These two nutrients should always be taken together; D3 drives calcium absorption, and K2 directs it appropriately.

Deficiency symptoms: Muscle weakness, bone pain, frequent illness, low mood, poor wound healing.

Omega-3 Fatty Acids (EPA & DHA)

EPA and DHA support cardiovascular health, reduce systemic inflammation, maintain brain structure, and preserve lean muscle mass. GLP-1-related weight loss is rapid enough that muscle preservation becomes a genuine concern — omega-3s activate muscle protein synthesis pathways and reduce the inflammatory signals that drive muscle catabolism. They also support the lipid remodelling that occurs as body composition shifts dramatically. Most GLP-1 users significantly reduce their intake of fatty fish, the primary dietary source.

Deficiency symptoms: Joint stiffness, dry skin, brain fog, increased inflammatory markers, low mood.

Probiotics

The gut microbiome is profoundly affected by GLP-1 medications — through altered motility, changed substrate availability as diet shifts, and possible direct effects on microbial populations. A disrupted microbiome contributes to bloating, irregular bowel habits (both constipation and diarrhoea are reported), reduced immune function, and impaired short-chain fatty acid production. Multi-strain probiotics with documented clinical strains help restore microbial balance and support the gut-brain axis, which GLP-1 medications also modulate.

Digestive Enzymes

Slowed gastric emptying changes the entire digestive cascade. Pancreatic enzyme secretion is reduced, bile acid cycling slows, and the pH environment in the small intestine shifts. The practical result: food is less completely digested, nutrient absorption is impaired, and undigested food reaching the colon causes fermentation — contributing to the bloating and discomfort common among GLP-1 users. Broad-spectrum digestive enzyme complexes support the breakdown of proteins, fats, and carbohydrates, improving both nutrient yield and gastrointestinal comfort.

3. Our 3 Curated Bundles

Choose the level of support that matches your needs and budget:

4. How to Take Your GLP-1 Stack

References

1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002. PMID: 33567185
2. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205–216. PMID: 35658024
3. Carman WS, et al. Micronutrient deficiencies following GLP-1 receptor agonist therapy: a systematic review. Obes Rev. 2023;24(8):e13584. PMID: 37194467
4. Perna S, et al. Magnesium supplementation in metabolic syndrome and type 2 diabetes: a systematic review. Magnes Res. 2018;31(4):120–132. PMID: 30540972
5. Yin J, et al. Efficacy of Berberine in Patients with Type 2 Diabetes Mellitus. Metabolism. 2008;57(5):712–717. PMID: 18442638